Interleukin-1 inhibition in Behçet’s disease

Antonio Vitale, Donato Rigante, Giuseppe Lopalco, Carlo Selmi, Mauro Galeazzi, Florenzo Iannone, Luca Cantarini

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Behçet’s disease (BD) is a systemic inflammatory disorder characterized by a protean clinical spectrum and an enigmatic pathogenesis. After being classified as an autoimmune disorder, spondyloarthritis and vasculitis, today BD is considered at the crossroad between autoimmune and auto-inflammatory syndromes. Many pathogenetic, clinical and therapeutic clues support this recent interpretation, enabling novel treatment choices such as interleukin (IL)-1 inhibition. Thus, in the last decade the IL-1 receptor antagonist anakinra and the anti-IL-1β monoclonal antibody canakinumab were increasingly administered in BD patients resistant to standard therapies, leading to interesting results and intriguing new pathogenetic implications. However, further studies are essential to both establish how the innate and acquired immune systems interact in BD patients and identify the best way of administering anti-IL-1 agents with regard to dosage, interval of administration, and organ response.

Original languageEnglish (US)
Pages (from-to)171-176
Number of pages6
JournalIsrael Medical Association Journal
Volume18
Issue number3-4
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Interleukin-1
Interleukin 1 Receptor Antagonist Protein
Interleukin-1 Receptors
Vasculitis
Immune System
Therapeutics
Monoclonal Antibodies

Keywords

  • Anakinra
  • Auto-inflammatory diseases
  • Behçet’s disease (BD)
  • Canakinumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vitale, A., Rigante, D., Lopalco, G., Selmi, C., Galeazzi, M., Iannone, F., & Cantarini, L. (2016). Interleukin-1 inhibition in Behçet’s disease. Israel Medical Association Journal, 18(3-4), 171-176.

Interleukin-1 inhibition in Behçet’s disease. / Vitale, Antonio; Rigante, Donato; Lopalco, Giuseppe; Selmi, Carlo; Galeazzi, Mauro; Iannone, Florenzo; Cantarini, Luca.

In: Israel Medical Association Journal, Vol. 18, No. 3-4, 01.03.2016, p. 171-176.

Research output: Contribution to journalArticle

Vitale, A, Rigante, D, Lopalco, G, Selmi, C, Galeazzi, M, Iannone, F & Cantarini, L 2016, 'Interleukin-1 inhibition in Behçet’s disease', Israel Medical Association Journal, vol. 18, no. 3-4, pp. 171-176.
Vitale A, Rigante D, Lopalco G, Selmi C, Galeazzi M, Iannone F et al. Interleukin-1 inhibition in Behçet’s disease. Israel Medical Association Journal. 2016 Mar 1;18(3-4):171-176.
Vitale, Antonio ; Rigante, Donato ; Lopalco, Giuseppe ; Selmi, Carlo ; Galeazzi, Mauro ; Iannone, Florenzo ; Cantarini, Luca. / Interleukin-1 inhibition in Behçet’s disease. In: Israel Medical Association Journal. 2016 ; Vol. 18, No. 3-4. pp. 171-176.
@article{d93cefdc11ed401cbcd156d142b74f0a,
title = "Interleukin-1 inhibition in Beh{\cc}et’s disease",
abstract = "Beh{\cc}et’s disease (BD) is a systemic inflammatory disorder characterized by a protean clinical spectrum and an enigmatic pathogenesis. After being classified as an autoimmune disorder, spondyloarthritis and vasculitis, today BD is considered at the crossroad between autoimmune and auto-inflammatory syndromes. Many pathogenetic, clinical and therapeutic clues support this recent interpretation, enabling novel treatment choices such as interleukin (IL)-1 inhibition. Thus, in the last decade the IL-1 receptor antagonist anakinra and the anti-IL-1β monoclonal antibody canakinumab were increasingly administered in BD patients resistant to standard therapies, leading to interesting results and intriguing new pathogenetic implications. However, further studies are essential to both establish how the innate and acquired immune systems interact in BD patients and identify the best way of administering anti-IL-1 agents with regard to dosage, interval of administration, and organ response.",
keywords = "Anakinra, Auto-inflammatory diseases, Beh{\cc}et’s disease (BD), Canakinumab",
author = "Antonio Vitale and Donato Rigante and Giuseppe Lopalco and Carlo Selmi and Mauro Galeazzi and Florenzo Iannone and Luca Cantarini",
year = "2016",
month = "3",
day = "1",
language = "English (US)",
volume = "18",
pages = "171--176",
journal = "Israel Medical Association Journal",
issn = "1565-1088",
publisher = "Israel Medical Association",
number = "3-4",

}

TY - JOUR

T1 - Interleukin-1 inhibition in Behçet’s disease

AU - Vitale, Antonio

AU - Rigante, Donato

AU - Lopalco, Giuseppe

AU - Selmi, Carlo

AU - Galeazzi, Mauro

AU - Iannone, Florenzo

AU - Cantarini, Luca

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Behçet’s disease (BD) is a systemic inflammatory disorder characterized by a protean clinical spectrum and an enigmatic pathogenesis. After being classified as an autoimmune disorder, spondyloarthritis and vasculitis, today BD is considered at the crossroad between autoimmune and auto-inflammatory syndromes. Many pathogenetic, clinical and therapeutic clues support this recent interpretation, enabling novel treatment choices such as interleukin (IL)-1 inhibition. Thus, in the last decade the IL-1 receptor antagonist anakinra and the anti-IL-1β monoclonal antibody canakinumab were increasingly administered in BD patients resistant to standard therapies, leading to interesting results and intriguing new pathogenetic implications. However, further studies are essential to both establish how the innate and acquired immune systems interact in BD patients and identify the best way of administering anti-IL-1 agents with regard to dosage, interval of administration, and organ response.

AB - Behçet’s disease (BD) is a systemic inflammatory disorder characterized by a protean clinical spectrum and an enigmatic pathogenesis. After being classified as an autoimmune disorder, spondyloarthritis and vasculitis, today BD is considered at the crossroad between autoimmune and auto-inflammatory syndromes. Many pathogenetic, clinical and therapeutic clues support this recent interpretation, enabling novel treatment choices such as interleukin (IL)-1 inhibition. Thus, in the last decade the IL-1 receptor antagonist anakinra and the anti-IL-1β monoclonal antibody canakinumab were increasingly administered in BD patients resistant to standard therapies, leading to interesting results and intriguing new pathogenetic implications. However, further studies are essential to both establish how the innate and acquired immune systems interact in BD patients and identify the best way of administering anti-IL-1 agents with regard to dosage, interval of administration, and organ response.

KW - Anakinra

KW - Auto-inflammatory diseases

KW - Behçet’s disease (BD)

KW - Canakinumab

UR - http://www.scopus.com/inward/record.url?scp=84963779823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963779823&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 171

EP - 176

JO - Israel Medical Association Journal

JF - Israel Medical Association Journal

SN - 1565-1088

IS - 3-4

ER -